Singapore markets close in 5 hours 31 minutes

Agios Pharmaceuticals, Inc. (AGIO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
27.93-0.67 (-2.34%)
At close: 04:00PM EST
27.93 0.00 (0.00%)
After hours: 04:01PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 1.73B
Enterprise value 1.09B
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)173.38
Price/book (mrq)1.65
Enterprise value/revenue 110.08
Enterprise value/EBITDA -2.83

Trading information

Stock price history

Beta (5Y monthly) 1.01
52-week change 3-6.47%
S&P500 52-week change 3-15.72%
52-week high 336.08
52-week low 316.75
50-day moving average 328.11
200-day moving average 326.20

Share statistics

Avg vol (3-month) 3558.65k
Avg vol (10-day) 3391.04k
Shares outstanding 554.94M
Implied shares outstanding 6N/A
Float 851.17M
% held by insiders 11.30%
% held by institutions 1105.33%
Shares short (14 Nov 2022) 46.31M
Short ratio (14 Nov 2022) 411.58
Short % of float (14 Nov 2022) 412.96%
Short % of shares outstanding (14 Nov 2022) 411.48%
Shares short (prior month 13 Oct 2022) 45.94M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)-3,974.84%

Management effectiveness

Return on assets (ttm)-18.13%
Return on equity (ttm)-30.01%

Income statement

Revenue (ttm)9.93M
Revenue per share (ttm)0.18
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -385.75M
Net income avi to common (ttm)-366.91M
Diluted EPS (ttm)-6.43
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)727.68M
Total cash per share (mrq)13.24
Total debt (mrq)89.98M
Total debt/equity (mrq)8.57
Current ratio (mrq)14.65
Book value per share (mrq)19.13

Cash flow statement

Operating cash flow (ttm)-327.41M
Levered free cash flow (ttm)-223.01M